Research & Development
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
ZETA SURGICAL reports first patient treated with Zeta TMS Navigation System at HOPE Therapeutics
24 June 2026 - Medical technology manufacturer ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq:NRXP), announced on Tuesday that the first patient has been treated with the ...
EU approves MAVIRET for acute hepatitis C treatment
23 June 2026 - Clinical-stage biotechnology company Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced on Tuesday that its partner AbbVie (NYSE:ABBV) has received European Commission approval for MAVI...
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that the European Commission has approved Cenrifki (tolebrutinib) for the treatment of second...
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
22 June 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the u...
Solvonis reports positive bridging data for SVN-002 ahead of planned US Phase 2b
22 June 2026 - Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) on Monday reported positive pharmacokinetic data from a preclinical bridging study supporting the development of SVN-002,...